Journal article icon

Journal article

GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia

Abstract:
Hippocampal hyperactivity driven by GABAergic interneuron deficits and NMDA receptor hypofunction is associated with the hyperdopaminergic state often observed in schizophrenia. Furthermore, previous research in the methylazoxymethanol acetate (MAM) rat model has demonstrated that repeated peripubertal diazepam administration can prevent the emergence of adult hippocampal hyperactivity, dopamine-system hyperactivity, and associated psychosis-relevant behaviors. Here, we sought to characterize hippocampal GABAA and NMDA receptors in MAM-treated rats and to elucidate the receptor mechanisms underlying the promising effects of peripubertal diazepam exposure. Quantitative receptor autoradiography was used to measure receptor density in the dorsal hippocampus CA1, ventral hippocampus CA1, and ventral subiculum. Specifically, [3H]-Ro15-4513 was used to quantify the density of α5GABAA receptors (α5GABAAR), [3H]-flumazenil to quantify α1-3;5GABAAR, and [3H]-MK801 to quantify NMDA receptors. MAM rats exhibited anxiety and schizophrenia-relevant behaviors as measured by elevated plus maze and amphetamine-induced hyperlocomotion (AIH), although diazepam only partially rescued these behaviors. α5GABAAR density was reduced in MAM-treated rats in all hippocampal sub-regions, and negatively correlated with AIH. Ventral hippocampus CA1 α5GABAAR density was positively correlated with anxiety-like behavior. Dorsal hippocampus CA1 NMDA receptor density was increased in MAM-treated rats, and positively correlated with AIH. [3H]-flumazenil revealed no significant effects. Finally, we found no significant effect of diazepam treatment on receptor densities, potentially related to the only partial rescue of schizophrenia-relevant phenotypes. Overall, our findings provide first evidence of α5GABAAR and NMDA receptor abnormalities in the MAM model, suggesting that more selective pharmacological agents may become a novel therapeutic mechanism in schizophrenia
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1038/s41386-021-01213-0
Publication website:
http://sro.sussex.ac.uk/id/eprint/106117/1/s41386-021-01213-0.pdf

Authors

More by this author
Role:
Author
ORCID:
0000-0001-6819-8090
More by this author
Role:
Author
ORCID:
0000-0003-1033-1850
More by this author
Role:
Author
ORCID:
0000-0001-5021-1234
More by this author
Role:
Author
ORCID:
0000-0002-4886-142X
More by this author
Role:
Author
ORCID:
0000-0002-8561-4241


Publisher:
Springer Nature [academic journals on nature.com]
Journal:
Neuropsychopharmacology More from this journal
Volume:
47
Issue:
3
Pages:
687-695
Publication date:
2021-11-06
DOI:
EISSN:
1740-634X
ISSN:
0893-133X


Language:
English
Keywords:
Pubs id:
1207688
Local pid:
pubs:1207688
Source identifiers:
W3212558380
Deposit date:
2026-03-26
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP